一个平台对聚合物和脂质纳米颗粒进行比较,用于输送安福特里辛B
Nandha Joyson1, Anchal Pathak1, Keerti Jain2
1Drug Delivery and Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) - Raebareli, Lucknow, Uttar Pradesh, 226002, India.
AAPS PharmSciTech
|November 9, 2023
概括
研究人员开发了新型的安二B (AmB) 纳米配方,以减少其毒性. 固体脂质纳米颗粒 (SLN) 和基于的纳米颗粒 (PNP) 促进了AmB的少毒单体形式,与原始药物相比,显示出降低了血液溶解.
科学领域:
- 纳米技术纳米技术
- 制药科学 制药科学
- 药用化学 医学化学
背景情况:
- 氨酸B (AmB) 是一种重要的抗真菌和抗原动物抗生素.
- AmB的毒性与其寡合形式有关,这些形式在人类细胞膜中与胆固醇有很高的亲和力.
- 开发AmB纳米配方可以通过偏好不那么有害的分子状态来潜在地减轻毒性.
研究的目的:
- 在固体脂质纳米颗粒 (SLN) 和基因纳米颗粒 (PNP) 中研究安二乙 (AmB) 的聚合状态.
- 对AmB纳米配方进行比较分析,以提高单体化和降低毒性.
- 评估这些纳米配方在改善AMB的治疗指数方面的潜力.
主要方法:
- 用AMB装载的SLN和PNP的制备和表征,包括粒子大小和泽塔电位测量.
- 在体外释放研究评估药物释放动力学从两个纳米配方.
- 紫外线可见和圆形二极化谱光测量以确定AmB.的聚合状态.
- 血液溶解测试用于评估纳米配方与纯AmB.B.相比的体外毒性.
主要成果:
- AmB-SLN和AmB-PNP的粒子大小不同 (分别为378.90 ± 9.50 nm和184.90 ± 6.00 nm) 和泽塔电位 (分别为-34.97 ± 0.51 mV和+28.93 ± 2.29 mV).
- 纳米颗粒中的Zeen和甘单酸盐促进了AmB的单形式,AmB-SLNs显示出更高的单化程度.
- 与SLN (86.33 ± 0.93%) 相比,PNP表现出更受控的AMB释放 (52.48 ± 1.07%).
- 两种AmB-SLNs和AmB-PNPs都显示出明显降低的血液溶解活性,与纯安二B相比.
结论:
- 纳米配方,特别是AmB-SLNs,可以有效地促进安二B的单体形式,降低其固有的毒性.
- 研究的纳米配方表现出较低的溶血活性,这表明安全性状况有所改善.
- 这些发现表明,AMB纳米配方在治疗真菌和原生动物感染方面有望提高选择性和疗效.
相关概念视频
01:17Pore Transport and Ion-Pair Transport
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...